Lyell Immunopharma, Inc. — Director's Dealing 2025

Jul 30, 2025

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Lyell Immunopharma, Inc. (LYEL)
CIK: 0001806952
Period of Report: 2025-07-25

Reporting Person: ARCH Venture Fund XIII, L.P. (10% Owner)
Reporting Person: ARCH Venture Partners XIII, L.P. (10% Owner)
Reporting Person: ARCH Venture Partners XIII, LLC (10% Owner)
Reporting Person: CRANDELL KEITH (10% Owner)
Reporting Person: NELSEN ROBERT (10% Owner)
Reporting Person: Burow Kristina (10% Owner)
Reporting Person: GILLIS STEVEN (10% Owner)
Reporting Person: BERNS PAUL L (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	938438	Indirect

Footnotes

F1: These shares were purchased on July 25, 2025 pursuant to a securities purchase agreement dated July 24, 2025 at a price per share of $13.32.

F2: These shares are directly held by ARCH Venture Fund XIII, L.P. ("ARCH XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC") is the general partner of AVP XIII LP. Keith Crandell, Robert Nelsen, Kristina Burow, Paul Berns and Steven Gillis are members of the investment committee of AVP XIII LLC (the "AVP XIII LLC Committee Members"). Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.